[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610661":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":11,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","EXPERIMENTAL",null,[13],"Biological: CM512",{"label":15,"type":10,"description":11,"interventionNames":16},"Group 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Group 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Group 4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"BIOLOGICAL","CM512","CM512 subcutaneous injection",[9,15,18,21],[30],{"name":31,"affiliation":32,"role":33},"Jianzhong Zhang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Qian Jia","CONTACT","+86-028-88610620","qianjia@keymedbio.com",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":31,"role":37,"phone":55,"phoneExt":11,"email":56},"15545433012","rmzjz@126.com",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610661","phase-2-a-long-term-safety-and-efficacy-study-evaluating-cm512-in-atopic-dermatitis-100610661",false,"NCT07230483","A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.","An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.","Inclusion Criteria:\n\n* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).\n* Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.","ALL","18 Years",{"count":69,"type":70},246,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.",[76],"Atopic Dermatitis (AD)","2025-11-13",{"date":79,"type":80},"2025-11-17","ACTUAL",{"date":82,"type":70},"2025-12",{"date":84,"type":70},"2027-12",{"name":5,"class":6},1]